Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Matthew S. Davids, MD, MMSc


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Clinical Research, Lymphoma Program
  • Physician
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Chronic lymphocytic leukemia
  • Lymphoma

Diseases Treated

  • Leukemia, Chronic Lymphocytic (CLL)
  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin

Contact Information

  • Appointments617-632-6246 (new)
    617-632-5847 (follow-up)
  • Office Phone Number617-632-5847
  • Fax617-582-7890

Bio

After obtaining an A.B. cum laude in chemistry at Harvard College, Dr. Davids completed his M.D. cum laude at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (M.M.S.c.) at Harvard Medical School. He is an attending physician in the Division of Lymphoma, where he serves as the Director of Clinical Research, as well as Associate Director of the CLL Center. He is also an Associate Professor of Medicine at Harvard Medical School, and attends on the inpatient hematologic malignancies service at Brigham and Women's Hospital. Dr. Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.

Board Certification:

  • Hematology, 2011
  • Internal Medicine, 2008
  • Medical Oncology, 2011

Fellowship:

  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center, Internal Medicine

Medical School:

  • Yale University School of Medicine

Research

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 Mar 15.
View in: PubMed

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 06; 397(10277):892-901.
View in: PubMed

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia Haematologica. 2021 02 25.
View in: PubMed

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 Feb 17.
View in: PubMed

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 02 01; 106(2):651-654.
View in: PubMed

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98.
View in: PubMed

Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review. Crit Rev Oncol Hematol. 2021 Feb; 158:103212.
View in: PubMed

Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745.
View in: PubMed

A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
View in: PubMed

miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors. Blood. 2020 11 10.
View in: PubMed

Idelalisib in indolent NHL - has it finally found its niche? Leuk Lymphoma. 2020 Oct 19; 1-2.
View in: PubMed

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clin Ther. 2020 10; 42(10):1955-1974.e15.
View in: PubMed

Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2020 Oct 05; Online ahead of print.
View in: PubMed

Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. Pharmacoecon Open. 2020 Sep 29.
View in: PubMed

Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 09 03; 136(10):1134-1143.
View in: PubMed

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. Pharmacoeconomics. 2020 09; 38(9):941-951.
View in: PubMed

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989.
View in: PubMed

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 2021 04; 35(4):1064-1072.
View in: PubMed

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
View in: PubMed

Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 2020 08; 95(8):E199-E203.
View in: PubMed

BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). Clin Cancer Res. 2020 07 15; 26(14):3514-3516.
View in: PubMed

Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. Lancet. 2020 04 18; 395(10232):1234-1236.
View in: PubMed

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 2020 04 14; 4(7):1458-1463.
View in: PubMed

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020 04 14; 4(7):1407-1418.
View in: PubMed

Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin. 2020 05; 36(5):843-852.
View in: PubMed

Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020 03 28; 395(10229):1078-1088.
View in: PubMed

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
View in: PubMed

Breaking through BCL-2 inhibition in CLL. Blood. 2020 03 05; 135(10):709-711.
View in: PubMed

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clin Cancer Res. 2020 05 01; 26(9):2096-2103.
View in: PubMed

Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events. J Am Acad Dermatol. 2019 Dec 20.
View in: PubMed

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
View in: PubMed

BCL-2 Inhibitors, Present and Future. Cancer J. 2019 Nov/Dec; 25(6):401-409.
View in: PubMed

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
View in: PubMed

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019 10 03; 134(14):1132-1143.
View in: PubMed

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
View in: PubMed

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428.
View in: PubMed

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938.
View in: PubMed

Venetoclax: R-CHOP rocket booster? Blood. 2019 05 02; 133(18):1922-1924.
View in: PubMed

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 07 11; 134(2):111-122.
View in: PubMed

Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. JAAD Case Rep. 2019 May; 5(5):401-405.
View in: PubMed

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174.
View in: PubMed

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019 11; 104(11):2258-2264.
View in: PubMed

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019 Jan; 6(1):e38-e47.
View in: PubMed

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol. 2019 06; 185(5):961-966.
View in: PubMed

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. J Clin Oncol. 2018 Oct 25; JCO1800359.
View in: PubMed

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leuk Lymphoma. 2019 05; 60(5):1312-1315.
View in: PubMed

A new triple threat to CLL. Blood. 2018 10 11; 132(15):1547-1548.
View in: PubMed

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
View in: PubMed

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 12 06; 132(23):2446-2455.
View in: PubMed

Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. Leuk Lymphoma. 2019 02; 60(2):527-530.
View in: PubMed

The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018 09 20; 132(12):1248-1264.
View in: PubMed

Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 06 13; 10(445).
View in: PubMed

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
View in: PubMed

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
View in: PubMed

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. Cancer Imaging. 2018 Apr 18; 18(1):13.
View in: PubMed

Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018 04 26; 131(17):1987-1989.
View in: PubMed

Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study. Leuk Lymphoma. 2018 10; 59(10):2327-2335.
View in: PubMed

Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018 03 08; 131(10):1073-1080.
View in: PubMed

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 04 12; 131(15):1704-1711.
View in: PubMed

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75.
View in: PubMed

Safety profiles of novel agent therapies in CLL. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):354-357.
View in: PubMed

How should we sequence and combine novel therapies in CLL? Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):346-353.
View in: PubMed

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):114-124.e2.
View in: PubMed

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv. 2017 Nov 28; 1(25):2433-2443.
View in: PubMed

IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017 Dec; 92(12):1393-1397.
View in: PubMed

Targeting BCL-2 in B-cell lymphomas. Blood. 2017 08 31; 130(9):1081-1088.
View in: PubMed

A complex case of ibrutinib treatment for a CLL patient on haemodialysis. Br J Haematol. 2018 06; 181(6):854-857.
View in: PubMed

Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017 Jun; 13(14):1223-1232.
View in: PubMed

Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail. 2017 05; 19(5):682-685.
View in: PubMed

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 2017 03 16; 17(1):198.
View in: PubMed

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2017 02; 12(1):11-19.
View in: PubMed

Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2075-2084.
View in: PubMed

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833.
View in: PubMed

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240.
View in: PubMed

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164.
View in: PubMed

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
View in: PubMed

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016 11 24; 128(21):2510-2516.
View in: PubMed

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13.
View in: PubMed

FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. Am J Hematol. 2016 10; 91(10):978-83.
View in: PubMed

Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 06 02; 374(22):2186-7.
View in: PubMed

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
View in: PubMed

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
View in: PubMed

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 06 23; 127(25):3215-24.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. BJR Case Rep. 2016; 2(1):20150271.
View in: PubMed

A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95.
View in: PubMed

Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
View in: PubMed

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22.
View in: PubMed

BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. Clin Cancer Res. 2015 Nov 15; 21(22):5021-9.
View in: PubMed

Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015 Sep; 170(5):694-703.
View in: PubMed

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clin Cancer Res. 2015 Jul 15; 21(14):3160-9.
View in: PubMed

The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2015 Mar; 10(1):18-27.
View in: PubMed

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8.
View in: PubMed

Imatinib mesylate (Gleevec?) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-189-93.
View in: PubMed

Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leuk Lymphoma. 2014 Dec; 55(12):2675-7.
View in: PubMed

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
View in: PubMed

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May; 10(6):957-67.
View in: PubMed

Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2014 Apr; 12(4):224-9.
View in: PubMed

Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014 Mar; 150(3):280-7.
View in: PubMed

Boldly Targeting Kinases without mutations. Blood. 2014 Feb 20; 123(8):1119-21.
View in: PubMed

Fatty intra-abdominal lymph nodes in chronic lymphocytic leukemia. Am J Hematol. 2014 Feb; 89(2):234-5.
View in: PubMed

Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.
View in: PubMed

Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013 Aug; 54(8):1823-5.
View in: PubMed

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
View in: PubMed

Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Apr; 27(2):329-39.
View in: PubMed

ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013 Feb 11; 23(2):139-41.
View in: PubMed

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17.
View in: PubMed

Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Dec; 53(12):2362-70.
View in: PubMed

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9.
View in: PubMed

BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203.
View in: PubMed

Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012 Sep 01; 30(25):3127-35.
View in: PubMed

Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol. 2012; 3(S1).
View in: PubMed

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011 Aug; 129(1):185-90.
View in: PubMed

Serum free light chain analysis. Am J Hematol. 2010 Oct; 85(10):787-90.
View in: PubMed

The molecular pathogenesis of myelodysplastic syndromes. . 2010 Aug 15; 10(4):309-19.
View in: PubMed

Medical management of radiation victims in the United States. Health Phys. 2010 Jun; 98(6):833-7.
View in: PubMed

Assessing surge capacity for radiation victims with marrow toxicity. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1436-41.
View in: PubMed

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol. 2009 Sep 10; 27(26):e97-100.
View in: PubMed

Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):22002.
View in: PubMed

STK25 is a candidate gene for pseudopseudohypoparathyroidism. Genomics. 2001 Sep; 77(1-2):2-4.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top